Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | ACE | P12821 | 4/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3713013 | 1.00 | ALDH1A1 (0.46) | ALDH1A1ACEL3MBTL1CNR2 | |
| SCHEMBL31097181 | 0.98 | ACE (0.46) | ACE | |
| SCHEMBL7338310 | 0.96 | ACE (0.49) | ALDH1A1ACE | |
| SCHEMBL7338312 | 0.96 | ACE (0.49) | ALDH1A1ACE | |
| SCHEMBL7763711 | 0.94 | ACE (0.50) | ACE | |
| SCHEMBL3795434 | 0.88 | CNR1 (0.47) | ACEL3MBTL1CNR2 | |
| SCHEMBL16238580 | 0.87 | CNR2 (0.49) | ACEL3MBTL1CNR2 | |
| SCHEMBL16237608 | 0.87 | CNR2 (0.49) | ACEL3MBTL1CNR2 | |
| SCHEMBL3708395 | 0.86 | CNR2 (0.49) | ACECNR2 | |
| SCHEMBL3710569 | 0.86 | CA2 (0.52) | ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0754176-B1 | NOVEL CARBAMATES AND UREAS AS MODIFIERS OF MULTI-DRUG RESISTANCE | VERTEX PHARMA (US) | 2001-12-05 | — | — | EP | claimed |
| US-8889670-B2 | Heterocyclic compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-18 | — | — | US | disclosed |
| US-20110312944-A1 | Heterocyclic Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312944-A1 | Heterocyclic Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | ALDH1A1 2533/4885ACE 3829/4885L3MBTL1 4308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.